Vaxcyte director Jacks Lee retires; Moncef Slaoui appointed to board

Vaxcyte, Inc.

Jacks Lee retired from the Board effective June 17, 2026; no disagreement with the company.
Lee entered a consulting agreement for global strategic supply and manufacturing operations.
Moncef Slaoui appointed as Class II director effective June 17, 2026; term expires at 2028 annual meeting.
Slaoui deemed independent under Nasdaq rules; will receive standard non-employee director compensation with annual equity grant valued at $430,000.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Moncef Slaoui

Class II Director

PCVX · Vaxcyte, Inc.

Effective: 2026-06-17
Filed: June 23, 2026, 4:09 PM ET

On June 17, 2026, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Moncef Slaoui to the Board as a Class II director, which appointment became effective immediately.

Departed

Jacks Lee

Director

PCVX · Vaxcyte, Inc.

Effective: 2026-06-17
Filed: June 23, 2026, 4:09 PM ET

On June 17, 2026, Jacks Lee notified the Board of Directors (the “Board”) of Vaxcyte, Inc. (“the “Company”) of his retirement from the Board, effective as of June 17, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Moncef Slaoui was appointed as Class II Director at Vaxcyte, Inc..

Action: appointed
Role: Class II Director

Exact text from the filing

On June 17, 2026, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Moncef Slaoui to the Board as a Class II director, which appointment became effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jacks Lee retired as Director at Vaxcyte, Inc..

Action: retired
Role: Director

Exact text from the filing

On June 17, 2026, Jacks Lee notified the Board of Directors (the “Board”) of Vaxcyte, Inc. (“the “Company”) of his retirement from the Board, effective as of June 17, 2026.

View on SEC.gov

Vaxcyte, Inc. filing history →

Source: SEC EDGAR

accession 0001649094-26-000026

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.